Nonconvulsive status epilepticus in metastatic CNS diseaseBLITSHTEYN, Svetlana; JAECKLE, Kurt A.Neurology. 2006, Vol 66, Num 8, pp 1261-1263, issn 0028-3878, 3 p.Article

Neoplastic meningitis from systemic malignancies: Diagnosis, prognosis and treatmentJAECKLE, Kurt A.Seminars in oncology. 2006, Vol 33, Num 3, pp 312-323, issn 0093-7754, 12 p.Article

Is There an Association Between Meningioma and Hormone Replacement Therapy?BLITSHTEYN, Svetlana; CROOK, Julia E; JAECKLE, Kurt A et al.Journal of clinical oncology. 2008, Vol 26, Num 2, pp 279-282, issn 0732-183X, 4 p.Article

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastomaJAECKLE, Kurt A; BALLMAN, Karla; FURTH, Alfred et al.Neurology. 2009, Vol 73, Num 15, pp 1207-1213, issn 0028-3878, 7 p.Article

Pathway analysis of primary central nervous system lymphomaTUN, Han W; PERSONETT, David; PARK, Peter J et al.Blood. 2008, Vol 111, Num 6, pp 3200-3210, issn 0006-4971, 11 p.Article

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical TrialGILBERT, Mark R; MEIHUA WANG; MAHAJAN, Anita et al.Journal of clinical oncology. 2013, Vol 31, Num 32, pp 4085-4091, issn 0732-183X, 7 p.Article

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme : North Central Cancer Treatment Group Study N0177BROWN, Paul D; KRISHNAN, Sunil; KUGLER, John W et al.Journal of clinical oncology. 2008, Vol 26, Num 34, pp 5603-5609, issn 0732-183X, 7 p.Article

Removal of an orbital metallic foreign body to facilitate magnetic resonance imaging : Technical case report. CommentaryDEEN, H. Gordon; MILLER, David A; KOSTICK, David A et al.Neurosurgery. 2006, Vol 58, Num 5, pp 999-999, issn 0148-396X, 1 p.Article

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious RisksSARKARIA, Jann N; GALANIS, Eva; GIANNINI, Caterina et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5573-5580, issn 1078-0432, 8 p.Article

Phase II evaluation of Temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium studyJAECKLE, Kurt A; HESS, Kenneth R; CLOUGHESY, Timothy et al.Journal of clinical oncology. 2003, Vol 21, Num 12, pp 2305-2311, issn 0732-183X, 7 p.Article

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisJAECKLE, Kurt A; BATCHELOR, Tracy; ROGERS, Lisa et al.Journal of neuro-oncology. 2002, Vol 57, Num 3, pp 231-239, issn 0167-594XArticle

A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaGILBERT, Mark R; DIGNAM, James J; JERAJ, Robert et al.The New England journal of medicine. 2014, Vol 370, Num 8, pp 699-708, issn 0028-4793, 10 p.Article

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group TrialGALANIS, Evanthia; KEITH ANDERSON, S; KAUFMANN, Timothy J et al.Clinical cancer research (Print). 2013, Vol 19, Num 17, pp 4816-4823, issn 1078-0432, 8 p.Article

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme : A North Central Cancer Treatment Group StudyGALANIS, Evanthia; JAECKLE, Kurt A; RICHON, Victoria M et al.Journal of clinical oncology. 2009, Vol 27, Num 12, pp 2052-2058, issn 0732-183X, 7 p.Article

Detrimental effects of tumor progression on cognitive function of patients with high-grade gliomaBROWN, Paul D; JENSEN, Ashley W; FELTEN, Sara J et al.Journal of clinical oncology. 2006, Vol 24, Num 34, pp 5427-5433, issn 0732-183X, 7 p.Article

PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074UHM, Joon H; BALLMAN, Karla V; SCHAEFER, Paul L et al.International journal of radiation oncology, biology, physics. 2011, Vol 80, Num 2, pp 347-353, issn 0360-3016, 7 p.Article

North Central Cancer Treatment Group : Achievements and PerspectivesGROTHEY, Axel; ADJEI, Alex A; ALBERTS, Steve R et al.Seminars in oncology. 2008, Vol 35, Num 5, pp 530-544, issn 0093-7754, 15 p.Article

Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: A north American brain tumor consortium trialCHANG, Susan M; PRADOS, Michael D; KUHN, John et al.Cancer. 2004, Vol 100, Num 8, pp 1712-1716, issn 0008-543X, 5 p.Article

Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiformeLEVIN, Victor A; UHM, Joon H; GLEASON, Mary Jo et al.Clinical cancer research. 2000, Vol 6, Num 10, pp 3878-3884, issn 1078-0432Article

NORTH CENTRAL CANCER TREATMENT GROUP PHASE I TRIAL N057K OF EVEROLIMUS (RAD001) AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORMESARKARIA, Jann N; GALANIS, Evanthia; WENTING WU et al.International journal of radiation oncology, biology, physics. 2011, Vol 81, Num 2, pp 468-475, issn 0360-3016, 8 p.Article

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patientsMARSHALL, Nicole E; BALLMAN, Karla V; MICHALAK, John C et al.Journal of neuro-oncology. 2006, Vol 77, Num 3, pp 315-320, issn 0167-594X, 6 p.Article

Phase III randomized study of postradiotherapy chemotherapy with combination α-difluoromethylornithine-PCV versus PCV for anaplastic gliomasLEVIN, Victor A; HESS, Kenneth R; GLEASON, Mary Jo et al.Clinical cancer research. 2003, Vol 9, Num 3, pp 981-990, issn 1078-0432, 10 p.Article

Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitisCOLE, Bernard F; GLANTZ, Michael J; JAECKLE, Kurt A et al.Cancer. 2003, Vol 97, Num 12, pp 3053-3060, issn 0008-543X, 8 p.Article

Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survivalPUDUVALLI, Vinay K; HASHMI, Masood; TOWNSEND, Jeannette J et al.Oncology. 2003, Vol 65, Num 3, pp 259-266, issn 0030-2414, 8 p.Article

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiformeGROVES, Morris D; PUDUVALLI, Vinay K; HESS, Kenneth R et al.Journal of clinical oncology. 2002, Vol 20, Num 5, pp 1383-1388, issn 0732-183XArticle